Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

pegylated IL-2 8MW2311

A polyethylene glycol (PEG)-conjugated form of the cytokine interleukin-2 (IL-2), with potential immunopotentiating and antineoplastic activities. Upon administration, pegylated IL-2 8MW2311 activates the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathway. This induces the proliferation of CD8+ T cells, enhances tumor cell killing and decreases tumor cell proliferation. Pegylation of IL-2 protects the cytokine from degradation.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	PEG-conjugated IL-2 8MW2311 pegylated interleukin-2 8MW2311
Code name:	8MW 2311 8MW-2311 8MW2311

pegylated IL-2 8MW2311

Search NCI's Drug Dictionary